Roche says Herceptin with chemo prolongs survival
ZURICH (Reuters) - Roche Holding AG's Herceptin, when added to chemotherapy Xeloda, prolonged survival without progression of breast cancer by three months compared to chemotherapy alone, the Swiss drugmaker said on Friday.
<p><img src="http://feeds.reuters.com/~a/reuters/healthNews?i=se3OJI" border="0"></img> (http://feeds.reuters.com/~a/reuters/healthNews?a=se3OJI)</p><div class="feedflare">
<img src="http://feeds.reuters.com/~f/reuters/healthNews?i=qh96gH" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=qh96gH) <img src="http://feeds.reuters.com/~f/reuters/healthNews?i=TpoWWh" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=TpoWWh) <img src="http://feeds.reuters.com/~f/reuters/healthNews?i=NMOe2h" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=NMOe2h)
</div><img src="http://feeds.reuters.com/~r/reuters/healthNews/~4/301172895" height="1" width="1"/>
http://feeds.reuters.com/~r/reuters/healthNews/~3/301172895/idUSL3043735120080530